Thyroid Cancer

Thyroid Cancer

A recent study found that women diagnosed with breast cancer are at increased risk for developing thyroid cancer, prompting the authors to encourage regular screening for the disease in breast cancer survivors.

Despite well-established guidelines from the American Thyroid Association, radioactive iodine continues to be overused for some forms of thyroid cancer.

The FDA has approved lenvatinib (Lenvima) for the treatment of patients with progressive, differentiated thyroid cancer refractory to radioactive iodine.

Researchers have uncovered two mutations in thyroid tumors that make the tumor either very sensitive to treatment with everolimus, or confers resistance.

Results of a new study show that cancer rates among children and adolescents are stable, but rates of certain cancers such as renal carcinomas are increasing.

Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.

This management guide of endocrine malignancies covers the risk factors, diagnosis, screening, and treatment of both thyroid and parathyroid cancers.


Subscribe to Thyroid Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.